Top Markets
#1 ONFA ONFA +225.76%
#2 Resolv wstUSR Resolv wstUSR +198.02%
#3 Noon Noon +41.33%
#4 Doge Strategy Doge Strategy +38.28%
#5 DeAgentAI DeAgentAI +38.13%
#6 NKN NKN +36.26%
#7 StakeStone StakeStone +28.59%
#8 BLOCKv BLOCKv +26.08%
#9 KONET KONET +24.91%
#10 OpenVPP OpenVPP +22.33%
Coin of the day
ONFA ONFA
Configurações
Idioma
PORTUGUêS
Moeda
USD
Tema
Ensysce Biosciences, Inc. Ensysce Biosciences, Inc.

Ensysce Biosciences, Inc.

ENSC
Classificação em ações #19706
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in... Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP prodrug candidate of oxycodone, which is in Phase II clinical trial for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat that is in Phase I clinical trial for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF329, an extended-release prodrug of hydromorphone that is similar to PF614; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse; and PF26810, an extended-release prodrug of methadone for opioid use disorder. The company is based in La Jolla, California.
Preço da ação
$0.5275
Valor de mercado
$1.25M
Variação (1 dia)
-3.56%
Variação (1 ano)
-83.77%
País
US
Negociar Ensysce Biosciences, Inc. (ENSC)

Categoria

Healthcare
Receita da Ensysce Biosciences, Inc. (ENSC)
Receita em Sep 2025 TTM: $4.49M
De acordo com os últimos relatórios financeiros da Ensysce Biosciences, Inc., a receita atual da empresa (TTM) é $4.49M. Em 2023, a empresa obteve uma receita de $2.23M uma diminuição em relação a a receita do ano 2022, que foi de $2.52M. A receita é o valor total gerado pela venda de bens ou serviços. Ao contrário do lucro, nenhuma despesa é subtraída.
Histórico de receita da Ensysce Biosciences, Inc. de 2017 a 2026
Receita no final de cada ano
Ano Receita Alterar
2026 (TTM) $4.49M -13.85%
2024 $5.21M 133.53%
2023 $2.23M -11.59%
2022 $2.52M -28.54%
2021 $3.53M -10.18%
2020 $3.93M 122.86%
2019 $1.76M 0.00%
2018 0.00 0.00%
2017 0.00 0.00%
Receita de empresas similares ou concorrentes
Empresa Receita Diferença de Receita País
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
 $48.44B 1,079,095.70%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.04B 268,123.28%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 $14.34B 319,469.02%
US
UCB SA UCB SA
UCB SA
UCB.BR
 $9.08B 202,258.79%
BE
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.70B 349,599.93%
AU